



## Long-Term Drug Shortage – Zerbaxa® (ceftolozane/tazobactam)

- The drug shortage of Merck's Zerbaxa (ceftolozane/tazobactam) injection is ongoing. Zerbaxa has been unavailable for at least 90 days due to requirements related to complying with good manufacturing practices.
  - Merck is the sole supplier of Zerbaxa and does not have an estimate as to when supply will be available.
  - The shortage was initially announced in January of 2021 and reverified by Merck on April 12, 2021.

Product Description	NDC#
Zerbaxa 1.5 g (ceftolozane/tazobactam) for injection is supplied in single-dose vials containing ceftolozane 1 g (equivalent to 1.147 g of ceftolozane sulfate) and tazobactam 0.5 g (equivalent to 0.537 g of tazobactam sodium) per vial	67919-030-01

- Zerbaxa is indicated for the treatment of complicated intra-abdominal infections, complicated urinary tract infections (including pyelonephritis) and for hospital-acquired bacterial pneumonia and ventilator-associated bacterial pneumonia.
- Other injectable antibiotics are available for healthcare providers to utilize.



OptumRx® specializes in the delivery, clinical management and affordability of prescription medications and consumer health products. We are an Optum® company — a leading provider of integrated health services. Learn more at [optum.com](https://www.optum.com).

All Optum® trademarks and logos are owned by Optum, Inc. All other brand or product names are trademarks or registered marks of their respective owners.

This document contains information that is considered proprietary to OptumRx and should not be reproduced without the express written consent of OptumRx.

RxNews® is published by the OptumRx Clinical Services Department.

©2021 Optum, Inc. All rights reserved.